A systematic review of selective and non-selective beta blockers for prevention of vascular events in patients with acute coronary syndrome or heart failure

Netherlands Journal of Medicine

Volumn 67, Issue 9, 2009, Pages 284-294

  De Peuter, O R ^a   Lussana, F ^a   Peters, R J G ^b   Buller H R ^a   Kamphuisen, P W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Epidemiology; Heart failure; Myocardial infarction; Pharmacology; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NEBIVOLOL; NITRIC ACID DERIVATIVE; PLACEBO; PROPRANOLOL; TIMOLOL; VASODILATOR AGENT;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL; HEART FAILURE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; METHODOLOGY; MORTALITY; RECEPTOR BLOCKING; REVIEW; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; HEART FAILURE; HUMANS; RISK;

EID: 70449111398     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). Circulation. 2007;116:e148-304.
2. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:e1-82.
3. Swedberg K, Cleland J, Dargie H, et al. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J. 2005;26:1115-1140
4. Werf vdF, Ardissino D, Betriu A, et al. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003;24:28-66.
5. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823 (Pubitemid 14035089)
6. Lopez-Sendon J, Swedberg K, McMurray J, et al. The Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25:1341-1362
7. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-1737 (Pubitemid 29290470)
8. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998;98:1184-1191 (Pubitemid 28436168)
9. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 2001;141:899-907. (Pubitemid 32477000)
10. Poole-Wilson PA, Swedberg K, Cleland JG, et al. COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.
11. Torp-Pedersen C, Poole-Wilson PA, Swedberg K, et al. COMET Investigators. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure. Am Heart J. 2005;149:370-376
12. Thrall G, Lane D, Carroll D, Lip GY. A systematic review of the effects of acute psychological stress and physical activity on haemorheology, coagulation, fibrinolysis and platelet reactivity: Implications for the pathogenesis of acute coronary syndromes. Thromb Res. 2007;120:819-847 (Pubitemid 47418227)
13. Von Kanel R, Dimsdale JE. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur J Haematol. 2000;65:357-369
14. Azevedo ER, Kubo T, Mak S, et al. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation. 2001;104:2194-2199 (Pubitemid 33043299)
15. Herman RB, Jesudason PJ, Mustafa AM, et al. Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. Br J Clin Pharmacol. 2003;55:134-138
16. Kohno T, Yoshikawa T, Yoshizawa A, et al. Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. Cardiovasc Drugs Ther. 2005;19:347-355 (Pubitemid 43029820)
17. Maclure M, Willett WC. Misinterpretation and misuse of the kappa statistic. Am J Epidemiol. 1987;126:161-169
18. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;2:823-827
19. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188
21. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101-105 (Pubitemid 32681979)
22. Manger Cats V, Capelle FJL, Lie KI, Durrer D. Effect of treatment with 2x100 mg metoprolol on mortality in a single-center study with low placebo mortality-rate after infarction. Circulation. 1983;68(suppl.3):181.
23. Salathia KS, Barber JM, McIlmoyle EL, et al. Very early intervention with metoprolol in suspected acute myocardial infarction. Eur Heart J. 1985;6:190-198 (Pubitemid 15063001)
24. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1985;55:471-475 (Pubitemid 15173090)
25. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin- converting enzyme inhibitors. Am J Cardiol. 1997;80:207-209 (Pubitemid 27329224)
26. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349:375-380
27. Basu S, Senior R, Raval U, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation. 1997;96:183-191
28. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707-1714
29. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-2816
30. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
31. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773
32. Cleland JG, Pennell DJ, Ray SG, et al. Carvedilol hibernating reversible ischaemia trial: marker of success investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet. 2003;362:14-21.
33. Cohn JN, Fowler MB, Bristow MR, et al. The US Carvedilol Heart Failure Study Group. Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 1997;3:173-179
34. Colucci WS, Packer M, Bristow MR, et al. The US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94:2800-2806
35. Dargie HJ, The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390
36. Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail. 2005;7:631-639 (Pubitemid 40732997)
37. Figulla HR, Krzeminska-Pakula M, Wrabec K, et al. Betaxolol is equivalent to carvedilol in patients with heart failure NYHA II or III: result of a randomized multicenter trial (BETACAR Trial). Int J Cardiol. 2006;113:153-160 (Pubitemid 44648380)
38. Flather MD, Shibata MC, Coats AJ, et al. The SENIORS investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-225
39. Hansteen V, Moinichen E, Lorentsen E, et al. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J (Clin Res Ed). 1982;284:155-160 (Pubitemid 12171752)
40. Jonsson G, Abdelnoor M, Muller C, et al. A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients. Cardiology. 2005;103:148-155 (Pubitemid 41094863)
41. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999;99:2645-2651 (Pubitemid 29237451)
42. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J. 1987;8:1056-1064
43. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007 (Pubitemid 29271744)
44. Metra M, Giubbini R, Nodari S, et al. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546-551 (Pubitemid 30642529)
45. Olsson G, Rehnqvist N, Sjogren A, Erhardt L, Lundman T. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol. 1985;5:1428-1437 (Pubitemid 15069520)
46. Packer M, Colucci WS, Sackner-Bernstein JD, et al. The PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE Trial. Circulation. 1996;94:2793-2799
47. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658 (Pubitemid 32479962)
48. Palazzuoli A, Quatrini I, Vecchiato L, et al. Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failure. J Cardiovasc Pharmacol. 2005;45:563-568 (Pubitemid 40734578)
49. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667
50. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807
51. Torp-Pedersen C, Kober L, Ball S, et al. The incomplete bucindolol evaluation in acute myocardial infarction Trial (BEAT). Eur J Heart Fail. 2002;4:495-499 (Pubitemid 36564970)
52. Waagstein F, Bristow MR, Swedberg K, et al. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-1446
53. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA. 1983;250:2814-2819
54. Gundersen T, Abrahamsen AM, Kjekshus J, Ronnevik PK, The Norwegian Multicentre Study Group. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation. 1982;66:1179-1184
55. Hansteen V. Beta blockade after myocardial infarction: the Norwegian propranolol study in high-risk patients. Circulation. 1983;67:157-160
56. Packer M, Fowler MB, Roecker EB, et al. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106:2194-2199
57. Pedersen TR, The Norwegian Multicenter Study Group. The Norwegian Multicenter Study of Timolol after Myocardial Infarction. Circulation. 1983;67:149-153.
58. Bonet S, Agusti A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med. 2000;160:621-627 (Pubitemid 30140411)
59. Doggrell SA. Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure? Expert Opin Pharmacother. 2004;5:205-208
60. Packer M. Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. J Card Fail. 2003;9:429-443 (Pubitemid 38055650)
61. de Boer RA, Voors AA, Van Veldhuisen DJ. Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother. 2007;8:1539-1550
62. Keating GM, Jarvis B. Carvedilol: a review of its use in chronic heart failure. Drugs. 2003;63:1697-1741 (Pubitemid 36999963)
63. Massie BM. A comment on COMET: how to interpret a positive trial? J Card Fail. 2003;9:425-428
64. Grant PJ. Hormonal regulation of the acute haemostatic response to stress. Blood Coagul Fibrinolysis. 1990;1:299-306.
65. Grignani G, Pacchiarini L, Zucchella M, et al. Effect of mental stress on platelet function in normal subjects and in patients with coronary artery disease. Haemostasis. 1992;22:138-146
66. Hoppener MR, Kraaijenhagen RA, Hutten BA, et al. Beta-receptor blockade decreases elevated plasma levels of factor VIII:C in patients with deep vein thrombosis. J Thromb Haemost. 2004;2:1316-1320